What Is an HGV Blood Test Used For?

An HGV blood test screens for hepatitis G virus, a bloodborne pathogen now formally called human pegivirus (HPgV). The test typically involves either detecting the virus’s genetic material in blood through molecular methods or measuring antibodies the immune system produces against it. Despite the alarming name, HGV has turned out to be one of the most benign viruses regularly found in human blood, and routine screening for it is not recommended in most countries. The story of HGV testing is less about diagnosing a dangerous infection and more about understanding a remarkably common virus that seems to do little harm.

What HGV Actually Is

Hepatitis G virus got its name during the mid-1990s flurry of discovery that followed the identification of hepatitis C. Researchers found a new RNA virus in human blood and, following the alphabetical convention of the hepatitis family, called it hepatitis G. The problem is that the name turned out to be misleading. The virus belongs to the family Flaviviridae but sits in its own genus, Pegivirus, rather than alongside the true hepatitis viruses.¹ The “pe” in Pegivirus stands for “persistent,” reflecting this virus’s tendency to set up long-term infections without causing obvious disease.²

The virus was also independently discovered by another team who named it GB virus C (GBV-C), after a surgeon whose initials were G.B. who had come down with hepatitis decades earlier. So in older medical literature you will see three names for the same thing: HGV, GBV-C, and HPgV. They all refer to the same virus. The current scientific consensus favors “human pegivirus type 1” (HPgV-1), but the shorthand “HGV” persists in clinical lab settings, which is why blood test orders still use it.

How the Blood Test Works

There are two fundamentally different ways to test for HGV, and they tell you different things about where a person stands in the course of infection.

The first method detects the virus itself. Laboratories use reverse-transcription PCR (RT-PCR) to find HGV RNA in a blood sample. This is the same basic technology used to detect hepatitis C and HIV. The test amplifies tiny fragments of viral genetic material so they can be identified. Early assays targeted sequences in the 5′ noncoding region of the viral genome as well as regions in the NS5a gene, and could pick up concentrations as low as a few hundred viral copies per milliliter of serum.³ Comparisons between commercial kits and in-house nested PCR methods showed that the nested approach was roughly ten times more sensitive, though commercial assays were still adequate for most clinical purposes.⁴

The second method looks for antibodies against the virus’s E2 envelope protein (anti-E2). This is an ELISA-based blood draw, similar in concept to the antibody tests most people are familiar with from hepatitis B or COVID-19 screening. Finding anti-E2 antibodies in someone’s blood generally means they were infected at some point and their immune system fought off the virus. Immunity appears to be long-lasting: antibodies have been detected as long as 14 years after the original infection resolved.⁵

What Your Results Mean

Interpreting HGV test results hinges on one distinctive feature of this virus: you almost never see HGV RNA and anti-E2 antibodies in the same person at the same time. The two markers are essentially inversely correlated. If your blood test finds HGV RNA, it means you have an active, ongoing infection. If it finds anti-E2 antibodies, it means you cleared the virus and developed immunity. A study of blood donors found that all five anti-E2-positive individuals were RNA-negative, confirming this seesaw pattern.⁶ Follow-up work in transfusion recipients showed the same thing: patients who developed anti-E2 antibodies became RNA-negative, while those who never mounted an antibody response stayed persistently infected.⁷

There is a diagnostic blind spot worth knowing about. Some people clear the virus but develop only a brief, undetectable antibody response. In a study of hemophilia patients, researchers found that the anti-E2 response could be transient or below the test’s detection threshold even after the virus had disappeared, which means a negative result on both tests does not definitively rule out past exposure.⁸ In practice, this gap matters more for epidemiological surveys than for individual patient care, since the infection is benign in the vast majority of people.

How Common Is HGV Infection

HGV is far more widespread than most people realize. Among healthy blood donors in southeastern France, about 2.6% carried active HGV RNA, and roughly 12% had anti-E2 antibodies indicating past infection.⁹ Adding those numbers together suggests that somewhere around one in seven donors in that population had been exposed at some point. Similar prevalence ranges have been reported from other countries, with rates generally higher in populations exposed to more blood products. Among people already positive for hepatitis C in the same French study, roughly 15% carried HGV RNA and nearly half had anti-E2 antibodies.

Hemodialysis patients and recipients of multiple blood transfusions tend to show even higher exposure. In an Iranian study, a quarter of hemodialysis patients had anti-E2 antibodies compared with 5% of volunteer blood donors.¹⁰ Among patients treated for leukemia and bone marrow transplant recipients, active HGV RNA was found in nearly half of those tested, with transplant recipients showing infection rates above 60%.¹¹

How HGV Spreads

The virus travels through the same routes as hepatitis B and C. Blood transfusions were the first recognized transmission pathway, and HGV can establish persistent infection after entering the bloodstream this way.¹² Injection drug use and receipt of blood products for conditions like hemophilia are major risk factors.

But parenteral routes do not account for all infections. Mother-to-child transmission is strikingly efficient. In one prospective study, HGV passed from actively infected mothers to their newborns in 75 to 80% of cases.¹³ A study of pregnant women in Tanzania who had no known risk factors for bloodborne infections still found HGV RNA in about 14% of them, with molecular evidence of vertical transmission to some of their children.¹⁴ Sexual transmission is also suspected, given how often HGV appears in people with no parenteral risk factors at all.

Does HGV Actually Cause Hepatitis

This is the central question that drove early interest in the virus, and the short answer is no. Despite its name, HGV does not behave like a liver virus. Research using highly sensitive strand-specific PCR found that the virus replicates primarily in bone marrow and spleen tissue, not in liver cells. Only one of four liver samples in that study showed any evidence of viral replication, while three of four bone marrow samples were positive.¹⁵ The virus grows in lymphocytes rather than hepatocytes, which is the fundamental reason it does not cause liver disease.¹⁶

Clinical studies have consistently reinforced this. A study of patients with chronic liver disease found that HGV infection played no significant role in liver damage, whether those patients had hepatitis B, hepatitis C, alcohol-related disease, or liver disease with no identifiable cause.¹⁷ A more recent investigation looking specifically at high-risk groups and chronic liver patients found no significant differences in liver enzyme levels or other markers of liver function between those with and without HGV infection.¹⁸

What about people who carry both hepatitis C and HGV at the same time? Multiple studies have examined this scenario. Among hepatitis C patients, the addition of HGV coinfection did not worsen liver inflammation, fibrosis scores, or response to interferon treatment.¹⁹ A separate analysis of 40 liver biopsies in coinfected and singly-infected patients found comparable inflammation scores and concluded that HGV coinfection “probably does not have a significant effect” on hepatitis C-related liver damage.²⁰ In liver transplant recipients with hepatitis C, HGV coinfection influenced neither transplant outcomes nor the rate at which hepatitis recurred in the new graft.²¹

The Unexpected HIV Connection

While HGV turned out to be a disappointment as a liver pathogen, it became unexpectedly interesting in HIV research. Several studies noticed that HIV-positive individuals who also carried HGV seemed to live longer than those who did not. A landmark study tracked HIV-positive patients and found that about 29% of those with active HGV coinfection died during follow-up, compared with 56% of those without HGV. After adjusting for treatment, immune status, age, and other factors, the mortality risk was about 3.7 times higher in patients who lacked HGV coinfection.²² Lab work from the same study showed that HGV infection inhibited HIV replication in cell cultures.

This was not a one-off finding. Multiple research groups reported similar survival benefits, and in vitro studies confirmed that GBV-C can interfere with HIV replication and alter the signaling molecules the immune system uses to fight infection.²³ A meta-analysis found that the benefit was particularly clear when HGV infection was present during established HIV disease rather than at the very earliest stages.²⁴

The mechanism appears to involve immune modulation rather than direct virus-on-virus combat. HGV interferes with T cell receptor signaling by reducing the activity of a key enzyme involved in early immune activation. This dials down the chronic immune activation that is a hallmark of HIV disease and one of its main drivers of harm, without suppressing the immune system outright. With enough stimulation, T cells still function normally.²⁵ In effect, HGV acts like a mild brake on immune overreaction, which in the context of HIV turns out to be helpful.

Why Blood Banks Do Not Screen for HGV

Given how easily HGV spreads through transfusions, you might expect blood banks to test for it. They generally do not, and the reason is straightforward: there is no evidence that receiving HGV-contaminated blood harms the recipient. As one review put it, HGV can be transmitted by transfusion and establish persistent infection, but “thus far it appears to have no discernible disease association.”²⁶ Screening blood products for a virus that causes no known illness would add cost without any measurable benefit to patient safety. This is why, despite widespread awareness of the virus among transfusion medicine specialists, no major blood banking authority has introduced routine HGV testing.

If you encounter an HGV blood test in clinical practice, it was almost certainly ordered as part of a research study, a workup for unexplained liver enzyme elevations (where it is increasingly recognized as a dead end), or as part of a broader panel investigating coinfections in an HIV-positive or immunocompromised patient. There is no standard clinical scenario in which an HGV test changes patient management.

HGV in Bone Marrow Transplant and Cancer Patients

One population where HGV test results show up more frequently is among people treated for blood cancers. Among bone marrow transplant recipients and leukemia patients, active infection rates reached about 48% in one cohort, with transplant patients at 61% compared with 33% in those on conventional chemotherapy.²⁷ The higher rates in transplant patients may reflect their heavier exposure to blood products. In pediatric bone marrow transplant recipients, HGV markers were found in about 20% of children tested, and RNA-positive survivors did show higher peak liver enzyme levels than those who were negative, though the clinical significance of that isolated finding remained uncertain.²⁸

A separate question is whether HGV might itself contribute to cancer. A case-control study found that active HGV infection was more than twice as common in patients with non-Hodgkin lymphoma compared with controls, and the association was strongest for diffuse large B-cell lymphoma, where the odds were about five times higher.²⁹ This association held even after excluding people with known risk factors like injection drug use and hepatitis C. The finding is intriguing given that HGV replicates in lymphocytes, but it has not been established whether the virus contributes to lymphoma development or whether something about lymphoma or its treatment simply makes people more susceptible to acquiring the virus.

Human Pegivirus 2, a Newer Relative

In 2015, researchers discovered a second human pegivirus, designated HPgV-2, in blood samples from people coinfected with hepatitis C. The new virus is genetically quite distinct from the original HPgV, sharing less than 32% amino acid similarity with its closest known relatives in bats and rodents.³⁰ Since its initial discovery in the United States, HPgV-2 has been detected in Vietnam, China, and Iran, almost always in people who also carry hepatitis C, particularly those with HIV/HCV coinfection.³¹

It is still too early to know whether HPgV-2 causes disease. Current commercial HGV blood tests were not designed to detect it, so if your lab results mention HGV or GBV-C, they are referring to the original virus. HPgV-2 detection currently requires specialized research assays. Whether it will eventually need its own screening test depends on whether it turns out to be another harmless hitchhiker or something with genuine clinical consequences, a question that remains open.